Covid-19 costs Coloplast USD 33m in extended court cases

Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.

Financial director Anders Lonning-Skovgaard | Photo: Niels Hougaard/ERH

In Coloplast's Q2 financial report released on Thursday there was a special column for the expensive cloud that is still hanging over the medtech company in the US.

This involves the court cases over the vaginal mesh developed by the company to treat uterine prolapse and urinary incontinence that are still haunting the company.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs